Malignant melanoma is the most malignant skin neoplasm due to early metastasis and resistance to currently available therapies. Inflammatory tumor infiltrate, particularly macrophages, are of outstanding importance for melanoma progression and therapy response. EphB4 receptor and its preferred ligand EphrinB2 are also associated with melanoma progression, metastasis, and therapy resistance.
OBJECTIVE:
The aim of our study was to systematically investigate the role of EphB4 for melanoma cell adhesion and migration, also in the presence of macrophages, considering experimental i) EphB4 overexpression, ii) EphB4 activation, iii) inhibition of EphB4 and EphrinB2 interaction, and iv) inhibition of EphB4 and downstream signaling.
RESULTS:
Overexpression of EphB4 resulted in increased A375 melanoma cell adhesion showing EphrinB2 reverse signaling rather than EphB4 forward signaling being responsible. By contrast, A375 melanoma cell migration was not affected by EphB4 overexpression and effects due to modulation of EphB4/EphrinB2 signaling were inconsistent. In co-culture experiments macrophages (HL-60(M)) showed substantial influence on adhesion and migration of A375 cells. However, HL-60(M)-mediated effects could not be assigned to EphB4/EphrinB2 signaling, but rather to cytokine signaling pathways.
CONCLUSIONS:
Under the used experimental settings EphB4 is important for adhesion, but not for the migration of A375 melanoma cells. Macrophages influenced adhesion and migration of melanoma cells but without significant involvement of EphB4/EphrinB2 signaling.
BoyleGM. Therapy for metastatic melanoma: An Overview and update. Expert Rev Anticanc. 2011;11(5):725–37.
2.
TandlerN, MoschB, PietzschJ. Protein and non-protein biomarkers in melanoma: A Critical update. Amino Acids. 2012;43(6):2203–30.
3.
BlessingK, MclarenKM. Histological regression in primary cutaneous melanoma: Recognition, prevalence and significance. Histopathol. 1992;20(4):315–22.
4.
RosenbergSA, YangJC, SherryRM, KammulaUS, HughesMS, PhanGQ, CitrinDE, RestifoNP, RobbinsPF, WunderlichJR, MortonKE, LaurencotCM, SteinbergSM, WhiteDE, DudleyME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011;17(13):4550–7.
5.
BrockerEB, ZwadloG, HolzmannB, MacherE, SorgC. Inflammatory cell infiltrates in human melanoma at different stages of tumor progression. Int J Cancer. 1988;41(4):562–7.
6.
TorisuH, OnoM, KiryuH, FurueM, OhmotoY, NakayamaJ, NishiokaY, SoneS, KuwanoM. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Peossible involvement of TNF alpha and IL-1 alpha. Int J Cancer. 2000;85(2):182–8.
7.
VarneyML, JohanssonSL, SinghRK. Tumour-associated macrophage infiltration, neovascularization and aggressiveness in malignant melanoma: Role of monocyte chemotactic protein-1 and vascular endothelial growth factor-A. Melanoma Res. 2005;15(5):417–25.
NeuberC, BelterB, MeisterS, HofheinzF, BergmannR, PietzschHJ, PietzschJ. Overexpression of receptor tyrosine kinase EphB4 triggers tumor growth and hypoxia in A375 Melanoma Xenografts: Insights from multitracer small animal imaging experiments. Molecules. 2018;23(2):444.
10.
MoschB, ReissenweberB, NeuberC, PietzschJ. Eph receptors and ephrin ligands: Important players in angiogenesis and tumor angiogenesis. J Oncol. 2010;135285.
11.
ChrencikJE, BroounA, RechtMI, KrausML, KoolpeM, KolatkarAR, BruceRH, Martiny-BaronG, WidmerH, PasqualeEB, KuhnP. Structure and thermodynamic characterization of the EphB4/ephrin-B2 antagonist peptide complex reveals the determinants for receptor specificity. Structure. 2006;14(2):321–30.
12.
ChenJ. Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv Cancer Res. 2012;114:1–20.
13.
VogtT, StolzW, WelshJ, JungB, KerbelRS, KobayashiH, LandthalerM, McclellandM. Overexpression of Lerk-5/Eplg5 messenger RNA: A Novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. Clin Cancer Res. 1998;4(3):791–7.
14.
Guijarro-MunozI, SanchezA, Martinez-MartinezE, GarciaJM, SalasC, ProvencioM, Alvarez-VallinaL, SanzL. Gene expression profiling identifies EPHB4 as a potential predictive biomarker in colorectal cancer patients treated with bevacizumab. Med Oncol. 2013;30(2):UNSP572.
15.
YangXK, YangYD, TangSQ, TangH, YangGH, XuQY, WuJJ. EphB4 inhibitor overcome the acquired resistance to cisplatin in melanomas xenograft model. J Pharmacol Sci. 2015;129(1):65–71.
IvanovAI, RomanovskyAA. Putative dual role of ephrin-Eph receptor interactions in inflammation. Iubmb Life. 2006;58(7):389–94.
18.
PasqualeEB. Eph-ephrin bidirectional signaling in physiology and disease. Cell. 2008;133(1):38–52.
19.
GiorgioC, MohamedIH, FlamminiL, BarocelliE, IncertiM, LodolaA, TognoliniM. Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. Plos One. 2011;6(3):e18128.
20.
DuggineniS, MitraS, NoberiniR, HanXF, LinN, XuY, TianW, AnJ, PasqualeEB, HuangZW. Design, synthesis and characterization of novel small molecular inhibitors of ephrin-B2 binding to EphB4. Biochem Pharmacol. 2013;85(4):507–13.
21.
DjokovicD, TrindadeA, GiganteJ, BadenesM, SilvaL, LiuR, LiX, GongM, KrasnoperovV, GillPS, DuarteA. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis. BMC Cancer. 2010;10:641.
22.
AbengozarMA, De FrutosS, FerreiroS, SorianoJ, Perez-MartinezM, OlmedaD, MarenchinoM, CanameroM, OrtegaS, MegiasD, RodriguezA, Martinez-TorrecuadradaJL. Blocking ephrinB2 with highly specific antibodies inhibits angiogenesis, lymphangiogenesis, and tumor growth. Blood. 2012;119(19):4565–76.
23.
NoberiniR, LambertoI, PasqualeEB. Targeting Eph receptors with peptides and small molecules: Progress and challenges. Semin Cell Dev Biol. 2012;23(1):51–7.
StephensonSA, DouglasEL, Mertens-WalkerI, LisleJE, MaharajMSN, HeringtonAC. Anti-tumour effects of antibodies targeting the extracellular cysteine-rich region of the receptor tyrosine kinase EphB4. Oncotarget. 2015;6(10):7554–69.
26.
TognoliniM, Hassan-MohamedI, GiorgioC, ZanottiI, LodolaA. Therapeutic perspecitves of Eph-ephrin system modulation. Drug Discov Today. 2014;19(5):661–9.
27.
MoschB, PietzschD, PietzschJ. Irradiation affects cellular properties and Eph receptor expression in human melanoma cells. Cell Adh Migr. 2012;6(2):113–25.
28.
MamatC, MoschB, NeuberC, KockerlingM, BergmannR, PietzschJ. Fluorine-18 Radiolabeling and Radiopharmacological Characterization of a Benzodioxolylpyrimidine-based Radiotracer Targeting the Receptor Tyrosine Kinase EphB4. Chemmedchem. 2012;7(11):1991–2003.
29.
RoveraG, SantoliD, DamskyC. Human promyelocytic leukemia cells in culture differentiate into macrophage-like cells when treated with a phorbol diester. Proc Natl Acad Sci USA. 1979;76(6):2779–83.
30.
TonderaC, LaubeM, PietzschJ. Insights into binding of S100 proteins to scavenger receptors: Class B scavenger receptor CD36 binds S100A12 with high affinity. Amino Acids. 2017;49(1):183–91.
31.
LafleurK, HuangDZ, ZhouT, CaflischA, NevadoC. Structure based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4). J Med Chem. 2009;52(20):6433–46.
32.
MamatC, NeuberC, MoschB, PietzschJ, SteinbachJ. Development and fluorine-18-radiolabeling of benzodioxolylpyrimidine EphB4 receptor inhibitors. J Labelled Compd Rad. 2011;54(Suppl 1):S178.
33.
ReissenweberB, MoschB, PietzschJ. Experimental hypoxia does not influence gene expression and protein synthesis of Eph receptors and ephrin ligands in human melanoma cells in vitro. Melanoma Res. 2013;23(2):85–95.
34.
KullanderK, KleinR. Mechanisms and functions of EPH and ephrin signalling. Nat Rev Mol Cell Bio. 2002;3(7):475–86.
35.
PalmerA, ZimmerM, ErdmannKS, EulenburgV, PorthinA, HeumannR, DeutschU, KleinR. EphrinB phosphorylation and reverse signaling: Regulation by Src kinases and PTP-BL phosphatase. Mol Cell. 2002;9(4):725–37.
36.
BardelleC, CrossD, DavenportS, KettleJG, KoEJ, LeachAG, MortlockA, ReadJ, RobertsNJ, RobinsP, WilliamsEJ. Inhibitors of the tyrosine kinase EphB4. Part 1: Structure-based design and optimization of a series of 2,4-bis-anilinopyrimidines. Bioorg Med Chem Lett. 2008;18(9):2776–80.
37.
RuoslahtiE. Fibronectin and its integrin receptors in cancer. Adv Cancer Res. 1999;76:1–20.
38.
NorenNK, YangNY, SilldorffM, MutyalaR, PasqualeEB. Ephrin-independent regulation of cell substrate adhesion by the EphB4 receptor. Biochem J. 2009;422:433–42.
39.
HeS, KumarSR, ZhouP, KrasnoperovV, RyanSJ, GillPS, HintonDR. Soluble EphB4 inhibition of PDGF-induced RPE migration in vitro. Invest Ophthalmol Vis Sci. 2010;51(1):543–52.
40.
AugustinHG, HeroultM, SchaffnerF, PfaffD, PrahstC, KirmseR, KutscheraS, RiedelM, LudwigT, VajkoczyP, GraeserR. EphB4 promotes site-specific metastatic tumor cell dissemination by interacting with endothelial cell-expressed ephrinB2. Mol Cancer Res. 2010;8(10):1297–309.
41.
KuhnP, ChrencikJE, BroounA, KrausML, RechtMI, KolatkarAR, HanGW, SeifertJM, WidmerH, AuerM. Structural and biophysical characterization of the EphB4-ephrinB2 protein-protein interaction and receptor specificity. J Biol Chem. 2006;281(38):28185–92.
42.
NeuberC, HerwigN, PietzschJ, BelterB. Limited importance of EphrinA1–ligand, Src kinase, and focal adhesion kinase in EphA2-mediated regulation of metastasis in Mel-Juso and A375 human melanoma cells. J Cell Biotechnol. 2019;5(1):11–26.
43.
YangNY, PasqualeEB, OwenLB, EthellIM. The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization. J Biol Chem. 2006;281(43):32574–86.
44.
SchwabeM, DeryuginaEI, BoscoMC, GusellaGL, ReinischW, KungHF, BourdonMA. IL-6 signals inhibition of cell adhesion in melanoma A375-C6. Anticancer Res. 1996;16(6B):3363–70.
45.
LuC, KerbelRS. Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 1993;120(5):1281–8.
46.
LiL, DragulevB, ZigrinoP, MauchC, FoxJW. The invasive potential of human melanoma cell lines correlates with their ability to alter fibroblast gene expression in vitro and the stromal microenvironment in vivo. Int J Cancer. 2009;125(8):1796–804.
47.
TodaroGJ, FrylingC, DelarcoJE. Transforming growth-factors produced by certain human-tumor cells - Polypeptides that interact with epidermal growth-factor receptors. P Natl Acad Sci-Biol. 1980;77(9):5258–62.
48.
FrancisGM, KrohnEG, WoodsKV, BuzaidAC, GrimmEA. Interleukin-6 production and secretion in human melanoma cell lines: Regulation by interleukin-1. Melanoma Res. 1996;6(3):191–201.
49.
YangNY, Lopez-BergamiP, GoydosJS, YipD, WalkerAM, PasqualeEB, EthellIM. The EphB4 receptor promotes the growth of melanoma cells expressing the ephrin-B2 ligand. Pigm Cell Melanoma Res. 2010;23(5):684–7.
50.
TakakuraN, HuangX, YamadaY, KidoyaH, NaitoH, NagahamaY, KongL, KatohSY, LiWF, UenoM. EphB4 overexpression in B16 melanoma cells affects arterial-venous patterning in tumor angiogenesis. Cancer Res. 2007;67(20):9800–8.
